SEC Form 4Coverage since May 11, 2026
$LYEL insider trading
Over the last 12 months, Lyell Immunopharma insiders reported no purchases and 7 sales totaling $41K across SEC Form 4 filings. 29% of the activity was filed under pre-arranged 10b5-1 trading plans.
- Bought · 12m
- — 0 events
- Sold · 12m
- $41K 7 events
- Events · 12m
- 7 Form 4 filings, grouped
- Insiders · 12m
- 6 distinct reporters
- 10b5-1 share
- 29% pre-arranged plans
Side
Price · $LYEL · 12Mvia TradingView
Top insiders · 12m
Innovative Cellular Therapeutics Holdings Ltd—2× · $274
Hill Stephen J.Chief Operating Officer1× · $2K
Lee Gary K.Chief Scientific Officer1× · $2K
Bulis Veronica SanchezVP, Corporate Controller1× · $4K
Seely LynnPresident and CEO1× · $7K
All insider trades
7 events
| Date | Insider | Type | Shares | Avg price | Value | Δ stake | Marks |
|---|---|---|---|---|---|---|---|
| Jul 17, 2026 | Innovative Cellular Therapeutics Holdings Ltd10% | ▼ Sale | 10 | $13.7 | $137 | — | plan |
| Jul 16, 2026 | Innovative Cellular Therapeutics Holdings Ltd10% | ▼ Sale | 10 | $13.73 | $137 | — | plan |
| Jun 10, 2026 | Shook DavidChief Medical Officer · O | ▼ Sale | 1,977 | $12.64 | $25K | -8.6% | — |
| May 11, 2026 | Seely LynnPresident and CEO · O·D | ▼ Sale | 388 | $18.91 | $7K | -0.5% | late |
| May 11, 2026 | Lee Gary K.Chief Scientific Officer · O | ▼ Sale | 130 | $18.92 | $2K | -0.7% | late |
| May 11, 2026 | Hill Stephen J.Chief Operating Officer · O | ▼ Sale | 89 | $18.92 | $2K | -0.5% | late |
| May 11, 2026 | Bulis Veronica SanchezVP, Corporate Controller · O | ▼ Sale | 217 | $18.91 | $4K | -1.4% | late |
About Form 4
Corporate insiders — officers, directors and 10%+ owners — must report their trades to the SEC on Form 4 within two business days. We group each filing's transactions into one economic event (a laddered 10b5-1 sale is one event, not 25 rows), flag pre-arranged plans and late filings, and link every event to its AI-scored article in the $LYEL feed.